Cargando…

Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis

OBJECTIVE: There has been limited systematic evaluation of outcomes and drivers of inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients with atrial fibrillation (AF). This review identified and systematically evaluated literature on clinical and economic outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caso, Valeria, de Groot, Joris R, Sanmartin Fernandez, Marcelo, Segura, Tomás, Blomström-Lundqvist, Carina, Hargroves, David, Antoniou, Sotiris, Williams, Helen, Worsley, Alice, Harris, James, Caleyachetty, Amrit, Vardar, Burcu, Field, Paul, Ruff, Christian T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872251/ https://www.ncbi.nlm.nih.gov/pubmed/36316100 http://dx.doi.org/10.1136/heartjnl-2022-321114

Ejemplares similares

Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey
por: Fuat, Ahmet, et al.
Publicado: (2023)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
por: Altman, Raul, et al.
Publicado: (2014)

Abstract 28. Novel Oral Anticoagulants (NOACs) in Microsurgery: A Review
por: Yao, Amy, et al.
Publicado: (2017)

New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
por: Altay, Servet, et al.
Publicado: (2017)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

Lack of reversibility for NOACs
por: Al-Kindi, Sadeer
Publicado: (2014)

TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022)

Consideration of NOACs (novel or non-vitamin K-dependent oral anticoagulants) in dental procedure
por: Song, Jiyoung
Publicado: (2021)

The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis
por: Udayachalerm, Sariya, et al.
Publicado: (2018)

Oral anticoagulation following bioprosthetic SAVR in patients with atrial fibrillation: what’s the current status of NOACs?
por: Milojevic, Milan, et al.
Publicado: (2022)

Response to ‘Lack of reversibility for NOACs’
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction
por: Singh, Balbir, et al.
Publicado: (2022)

Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials
por: Noseworthy, Peter A., et al.
Publicado: (2017)

Erratum to: Practice-derived data on Non-vitamin K antagonist Oral Anticoagulant (NOAC) therapy to complement observations from randomized trials
Publicado: (2020)

Assessment of treatment patterns and patient awareness in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants (ASPECT-NOAC)
por: Badak, Özer, et al.
Publicado: (2022)

The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
por: Grymonprez, M, et al.
Publicado: (2023)

Reversal agents for NOACs: Connecting the dots
por: Dalal, Jamshed, et al.
Publicado: (2016)

A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
por: Lindahl, Tomas L., et al.
Publicado: (2017)

Evaluating equality in prescribing Novel Oral Anticoagulants (NOACs) in England: The protocol of a Bayesian small area analysis
por: Rezaei-Darzi, Ehsan, et al.
Publicado: (2021)

Antibiotic-Eluting Envelopes for the Prevention of Cardiac Implantable Electronic Device Infections: Rationale, Efficacy, and Cost-Effectiveness
por: Traykov, Vassil, et al.
Publicado: (2022)

Prevention of cardiac implantable electronic device infections: guidelines and conventional prophylaxis
por: Blomstrom-Lundqvist, Carina, et al.
Publicado: (2021)

DVT prophylaxis in critical care: role of NOACS
por: Lancé, Marcus D.
Publicado: (2019)

Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
por: Li, Ze, et al.
Publicado: (2022)

Assessing Adherence and Persistence to Non-vitamin K Antagonist Oral Anticoagulants (NOACs) among Patients with Atrial Fibrillation in Tertiary-care Referral Centers in Malaysia
por: Kubas, Mohammed A, et al.
Publicado: (2020)

Left atrial function after epicardial pulmonary vein isolation in patients with atrial fibrillation
por: Bagge, Louise, et al.
Publicado: (2017)

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands
por: van den Heuvel, J. M., et al.
Publicado: (2018)

Repolarization abnormalities unmasked with a 252‐lead BSM system in patients with ARVC and healthy gene carriers
por: Kommata, Varvara, et al.
Publicado: (2022)

Catheter ablation of symptomatic atrial fibrillation: Sex, ethnicity, and socioeconomic disparities
por: Björkenheim, Anna, et al.
Publicado: (2022)

Epicardial conduction abnormalities in patients with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) and mutation positive healthy family members – A study using electrocardiographic imaging
por: Kommata, Varvara, et al.
Publicado: (2023)

Cardiac device infection: removing barriers to timely and adequate treatment
por: Atar, Dan, et al.
Publicado: (2023)

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
por: Li, Ze, et al.
Publicado: (2022)

Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs
por: Komen, Joris, et al.
Publicado: (2017)

Evaluation of a prompt card for community pharmacists performing consultations with patients on anticoagulation – lessons learned
por: Arnet, Isabelle, et al.
Publicado: (2018)

The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey
por: Potpara, Tatjana S., et al.
Publicado: (2017)

Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial
por: Polymeris, Alexandros A., et al.
Publicado: (2023)

Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study
por: Paciaroni, Maurizio, et al.
Publicado: (2017)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020)

Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding
por: Lee, Min-Taek, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vv7ond851h6vutj242m3tnik6g